Alex Bodell is a mechanical engineer and product development leader with over a decade of experience building hardware solutions for startups. He has driven the design and commercialization of robotic systems that automate tissue handling and lymph node recovery, enabling pathology labs to deliver faster and more consistent cancer diagnostics.
Ted Snelgrove is a commercial executive and industry veteran with 35 years of experience in therapeutics and diagnostics across oncology, immunology, and pathology. He has held leadership roles at companies including Eli Lilly, Amgen, Genomic Health, and Guardant Health, and has advanced novel solutions through more than a dozen life science startups to make healthcare more personalized and affordable.
Michael Dugan, M.D. is a board-certified pathologist and biotech executive with over 35 years of experience in molecular diagnostics and laboratory medicine. He has held senior medical leadership roles at Biocept, Exact Sciences, Genzyme Genetics, and others, advancing novel oncology diagnostics including liquid biopsy assays and companion diagnostics for cancer detection, staging, and therapy selection.
Gary Grossman is a commercial sales executive with over 25 years of experience in the pharmaceutical and biotechnology industries. He has held senior leadership roles at NX Development Corp., Medac Pharma, and as co-founder of BioPharm Strategic Solutions, specializing in building and scaling commercial organizations for innovative therapies.
Daniel Snelgrove is an R&D and AI leader specializing in robotics, computer vision, and machine learning for automated pathology workflows. He focuses on advancing hands-free tissue processing and AI-powered tools that improve consistency, throughput, and diagnostic quality in anatomic pathology labs.
John Kollins is a biopharma CEO and entrepreneur with over 35 years of experience leading private and public companies focused on discovering, developing, and commercializing innovative therapeutics. He has raised hundreds of millions in equity capital and completed strategic transactions including partnerships, mergers, and acquisitions.
Stan Lapidus has over three decades of experience pioneering technologies for early cancer detection. He founded Cytyc Corporation, which transformed cervical cancer screening and was acquired for $6 billion, and later established Exact Sciences, building a company whose valuation exceeded $22 billion.
Robert Michel founded and served as editor-in-chief of The DarkReport, a leading clinical laboratory intelligence service, since 1995. With over 25 years in the industry, including executive rolesat Nichols Institute, he is a recognized expert on laboratory business and economics whose work has appeared in The Wall Street Journal, Business Week, and Forbes.
Michael Schulhof is Chairman of GTI Holdings, a New York firmfocused on private equity investments and advisory services inaerospace, healthcare, energy, and media. He previously served as President and CEO of Sony Music and Sony Corporation of America. He sits on the boards of the Guggenheim Foundation and Brookings Institution and is a member of the Council on Foreign Relations.